Nascent Biotech is a pioneering company in the biotechnology sector, specializing in the development of human antibodies for cancer treatment. Their flagship product, Pritumumab, is a proprietary monoclonal antibody that targets a unique antigen on cancer cells. Pritumumab has received FDA orphan drug status, which is granted to drugs intended for the treatment of rare diseases. This status not only underscores the potential efficacy of Pritumumab but also provides certain benefits like market exclusivity and tax credits, enhancing its commercial viability.

The company primarily serves the healthcare and pharmaceutical markets, focusing on patients suffering from rare forms of cancer. Nascent Biotech operates on a business-to-business (B2B) model, collaborating with pharmaceutical companies, research institutions, and healthcare providers to bring their innovative treatments to market. Revenue is generated through licensing agreements, partnerships, and potentially, direct sales of their proprietary treatments once they receive full regulatory approval.

Nascent Biotech leverages its deep understanding of the human immune system to develop treatments that boost and regulate immune responses. This approach not only aims to treat cancer but also to improve the overall efficacy and safety of immunotherapy treatments.

Keywords: monoclonal antibody, cancer treatment, FDA orphan drug, biotechnology, Pritumumab, immune system, rare diseases, healthcare, pharmaceutical, immunotherapy.